Fluid overload (FO) is commonly seen during hospitalization for allogeneic hematopoietic stem-cell transplantation (AHSCT). We hypothesized that FO is associated with transplant outcomes and evaluated this complication in two cohorts of patients and graded based on post-transplant weight gain, symptoms, and need for treatment, and was scored in real time by an independent team. The first cohort (study cohort) underwent haploidentical transplantation for hematologic malignancies (N=145) following a melphalan-based conditioning regimen. In univariate analysis, factors associated with Day 100 non-relapse mortality (NRM) were FO Grade ≥2 (HR=15, CI 4.2–55, p<0.001), creatinine >1 mg/dL (HR=4.7, CI 1.6–14, p=0.005), and age >55 years (HR=4.5, CI 1.5–13, p=0.008). In multivariate analysis, factors associated with Day 100 NRM were FO Grade ≥2 (HR=13.1, CI 3.4–50, p<0.001) and creatinine >1 mg/dL at transplant admission (HR=3.5, CI 1.1–11, p=0.03). These findings were verified in a separate cohort (validation cohort) of patients with acute myeloid leukemia/myelodysplastic syndrome who underwent HLA-matched transplant (N=449) with busulfan-based conditioning. In multivariate analysis, factors associated with Day 100 NRM were FO Grade ≥2 (HR=34, CI 7.2–158, p<0.001) and, in patients with FO Grade <2, advanced disease status (HR=5, CI 1.1–22, p=0.03). A higher NRM translated to significantly poorer 1-year overall survival rates for patients with FO ≥2 than for patients without FO, 70% vs. 42% (p<0.001) in the study cohort and 64% vs. 38% (p<0.001) in the validation cohort. In conclusion, FO Grade ≥2 is strongly associated with higher NRM and shorter survival and should be considered an important prognostic factor in transplantation.